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Abstract
Background/Aim. The natural history of hepatitis C vi-
rus (HCV) infection is variable and the factors deter-
mining the course of the illness are unclear. There are
geographical variations in the distribution of different
HCV genotypes, and some of them are related to the
specific infection routes. Regarding our country, the
dominant genotype is genotype 1b. It is unclear and still
remains a question whether the distinct histopathological
manifestations are related to the particular genotypes of
HCV. Thus, the aim of this study was to determine
whether the distinct histopathological manifestations of
HCV infection might be in relation to the individual vi-
rus genotype. Methods. In this study we examined 126
patients with chronic HCV infection regarding the histo-
pathological features, demographic data, and virus geno-
type. The observed groups of patients were predomi-
nantly infected with HCV genotypes 1b and 3a. Results.
In this study we found that the patients infected with
HCV genotype 1b had more frequently moderate or se-
vere necroinflammatory activity of the disease, signifi-
cantly higher grading score as compared with other
genotypes (p < 0.0001). A higher degree of fibrosis was,
also, more common in the patients infected with geno-
type 1b of HCV as compared with other genotypes (p <
0.05). There were no significant correlations between the
necroinflammatory activity of the disease and the stage
of fibrosis in 1b, 4 and mixed genotypes. Conclusion.
The present data support the hypothesis that distinct
genotypes of HCV are associated with the particular
histopathological manifestation of the disease.
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Apstrakt
Uvod/Cilj. Prirodni tok hronične hepatitis C virusne in-
fekcije (HCV) je različit i nije potpuno objašnjeno koji sve
faktori utiču na tok bolesti. Poznato je da postoje geograf-
ske varijacije u distribuciji različitih genotipova virusa i ova
različitost najčešće je povezana sa specifičnim načinom
prenosa bolesti u pojedinim regionima. U našoj zemlji
dominanatan je genotip 1b. Uprkos novijim saznanjima o
samoj HCV infekciji i njenom lečenju, još uvek je nejasno i
postavlja se pitanje da li je i u kojoj meri histopatološki
nalaz povezan sa genotipom virusa izazivača bolesti. Cilj
ove studije bio je da se utvrdi da li bi jasne histopatološke
manifestacije HCV infekcije mogle biti u vezi sa individu-
alnim genotipom virusa. Metode. Našim istraživanjem
bilo je obuhvaćeno 126 bolesnika sa verifikovanom
hroničnom HCV infekcijom i praćena je povezanost his-
topatološkog nalaza, demografskih podataka i genotipa vi-
rusa. U našoj grupi ispitanika dominirali su bolesnici sa
genotipom 1b i 3a. Rezultati. Histopatološka evaluacija
pokazala je da bolesnici inficirani genotipom 1b imaju
češće srednje tešku ili tešku nekroinflamatornu aktivnost
bolesti, kao i značajno viši grading skor u poređenju sa
bolesnicima zaraženim drugim genotipovima virusa (p <
0,0001). Fibroza je, takođe,  češća kod bolesnika sa
genotipom 1b u poređenju sa drugim genotipovima (p <
0,05). U našoj grupi ispitanika nismo pronašli značajnu ko-
relaciju između nekroinflamatorne aktivnosti bolesti i sta-
dijuma fibroze kod inficiranih genotipom 1b, 4 i mešanim
genotipom. Zaključak. Naše istraživanje potvrđuje hipo-
tezu da genotip virusa može da bude značajan za histopa-
tološke karakteristike bolesti.
Ključne reči:
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Introduction
Chronic hepatitis C virus (HCV) infection is a disease
with a wide clinical spectrum ranging from ″asymptomatic
carriers″ to patients with fatal decompensated liver cirrhosis
and primary liver cancer 
1−6. According to the World Health
Organization (WHO) Report of 2002 
7, in 2001, chronic liver
diseases were responsible for 1.4 million deaths, including
796  000 due to cirrhosis and 616 000 due to primary liver
neoplasms. At least 20% of these deaths are probably attribut-
able to HCV infection − more than 280 000 deaths. Chronic
hepatitis C (CHC) is not the consequence of the direct de-
struction of hepatic cells by the virus. Rather, it results from an
intermediate immune response that is large enough to induce
hepatic cell destruction and fibrosis but not enough to eradi-
cate the virus from its reservoirs 
8. Quantitatively, HCV spe-
cific CD4 and CD8 T-cell responses are weaker in the chronic
phase than in the acute phase of the infection 
9. Histopatho-
logically, inflammatory activity is less pronounced in chronic
HCV infection when compared to liver lesions caused by
hepatitis B virus infection. Also, the typical ″ground glass″ in-
clusions within hepatocytes, which are characteristic for cyto-
plasmic hepatitis B surface antigen expression, are not appar-
ent in liver sections from chronically HCV-infected patients 
10.
In contrast, typical hepatic lesions in chronic HCV infection
might include bile duct damage, steatosis, or intraportal lym-
phoid clusters or follicles 
11, 12. HCV consists of six genotypes
which do not change during the course of infection. Genotype-
specific differences both within the translated and nontranslated
regions of the genome have been suggested to be responsible for
the different clinical manifestations of the disease. For instance,
group-specific sequences both at the 3' and 5' terminus of the
HCV genome have been suggested to be related to the differ-
ences in viral replication, translation, and pathogenicity among
the different groups of HCV isolates 
13, 14. The knowledge of
genotype is helpful for the prediction of sustained virological
response and the choice of treatment duration 
15. Also, several
European studies have suggested that genotype 1b might be
linked to the severity of liver disease 
16, 17, while some others
might not 
18, 19. However, it has not been sufficiently clarified
whether the prognosis differs among hepatitis C patients in-
fected with different genotypes.
The present study was aimed to evaluate whether distinct
histopathological manifestations of HCV infection might be
associated with the individual viral genotypes.
Methods
Patients. A total of 126 patients infected with HCV as di-
agnosed by the presence of anti–HCV antibodies and HCV
RNA in serum were studied prospectively (57 male, and 57
female patients, mean age 38 years, range 18−65). The patients
were considered the candidates for the peginterferon-α2a ther-
apy. Liver biopsies were performed as a part of a routine clini-
cal evaluation. Chronicity was proven by histopathology, vi-
rologically and biochemically according to the established
criteria: active virus replication (HCV RNA positivity), pres-
ence of anti–HCV antibody, elevated serum alanine amino-
transferase (ALT) activities observed for a period longer than
6 months. The patients with active hepatitis B virus or human
immunodeficiency virus infection and alcohol or drug abusers
were excluded from the study. The following exclusion criteria
were applied: clinical and biochemical evidence of the ad-
vanced disease, such as decompensate cirrhosis, serum albu-
min < 35 g/l, platelet count < 100 000/µl, white cell count <
3 500/µl, anemia (hemoglobin concentration of < 120 g/l in
women and 130 g/l in men), psychiatric conditions, uncon-
trolled diabetes, autoimmune diseases, pregnancy or con-
comitant significant medical illnesses.
Histopathological evaluation
Since 2002, 167 transcutaneous liver biopsies have been
performed. Hepatic biopsy is the gold standard exam to estimate
the severity of tissue damage in chronic hepatitis and to deter-
mine histological activity. The estimation of fibrosis progression
and the knowledge concerning associated factors in chronic
hepatitis C is extremely important for understanding its natural
history. The patients were submitted to a percutaneous hepatic
biopsy, when clinically indicated. In this study, only liver biop-
sies of at least 20 mm length with a minimum of 11 portal tracts
were included. The biopsy fragments were submitted to the
conventional histological procedures. All the samples were fixed
in formalin, embedded in paraffin wax and stained with
haemotoxylin and eosin, chromotrope aniline blue, Perl's iron
stain, PAS after diastase digestion, and Shikata's orcein. Grading
for activity and staging of fibrosis were performed by the Ishak's
scoring system 
20. Ishak's histological activity index (HAI) score
consists of the following separate categories:
 Grading HAI score
Necroinflammatory score consist of:
− periportal or periseptal interface hepatitis (piecemeal
necrosis, range 0−4);
− confluent necrosis (range 0−6);
− focal (spotty) lytic necrosis, apoptosis and focal in-
flammation (range 0−4);
− portal inflammation (range 0−4);
Staging HAI score
− staging of fibrosis: architectural changes, fibrosis and
cirrhosis (range 0−6)
Thus, necroinflammatory changes or the activity of
hepatitis, respectively, were graded: absent (score 0), mild
(score 1), moderate (score 3), or severe/marked (4 for all
categories, except for category B (score 4−6). Architectural
alterations were graded: absent (score 0, no fibrosis), mild
(score 1−2, portal fibrosis expansion), moderate (score 3−4,
portal-portal septa and portal-central), marked (score 5,
bridging fibrosis, P-P and/or P-C septa and occasional nod-
ules) and cirrhosis (score 6).
Histopathological evaluation was performed by trained
pathologist without the knowledge of the patients' biochemi-
cal or clinical data, respectively.
Qualitative HCV analysis
Serological blood examination evidenced anti−HCV
positivity in two samples, which were obtained in an one-
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using PCR method (Amplicor, Roche Diagnostics). The re-
sults of viral RNA titers in clinical samples are expressed as
the number of viral copies per ml (copies/ml).
Determination of the genotype
Viral genotype was determined using the Line probe as-
say (LiPa, Innogenetics, Ghent, Belgium). The HCV geno-
types were designed according to the nomenclature proposed
by the Simmond's classification, which distincts five HCV
RNK genotypes: 1b, 2a, 3, 4 and mixed genotype.
Statistical analysis
Descriptive statistical analyses were performed, and the
results were presented as the mean ± standard error (SEM).
Baseline data were descriptively summarized and the assess-
ment of the differences was completed using a Microsoft Ex-
cel program and analysis was carried out using a GrapPad
Prism/Instat 1.1 (GraphPad Software, California, USA). Dif-
ferences between parameters were tested by one of the fol-
lowing tests: the Students t test, Fisher's exact test and one-
way analysis of variance (ANOVA) followed by Dunnett's or
Bonferroni's multiple comparison post-hoc significance test-
ing. Absolute frequencies were statistically compared using
the χ
2 test. Correlations were tested by Spearman or Pearson
tests. A p value of less than 0.05 was considered to indicate
significance (p > 0.05 considered not statistically significant).
Results
Analysis of demographic parameters in patients with
chronic HCV infection in relation to virus genotype
Age and sex distribution of 126 patients with chronic
HCV infection was compared with respect to virus geno-
type (Table 1). The patients infected with HCV type 1b
were found to be older on average than the patients infected
with type 3a and 4 (p  < 0.001, p < 0.05 respectively,
ANOVA, Bonferroni's multiple comparison post-hoc test).
Also, the patients infected with HCV type 2 were found to
be older on average than the patients infected with type 3a,
4 and mixed genotype (p < 0.001, p < 0.001, p < 0.01 re-
spectively, ANOVA, Bonferroni's multiple comparison
post-hoc test). The whole group had the similar duration of
the disease before the study: 2 years on average, (ranging
from 6 months to 8 years), and we did not find any signifi-
cant difference in the duration of the disease in respect to
virus genotype.
Histopathological manifestations of chronic HCV
infection in relation to virus genotype
A total of 126 liver biopsy specimens from the patients
being chronically infected with HCV genotype 1b, 2, 3a, 4
and mixed were evaluated histopathologically.
The data were analyzed by the statistical means and
significant differences in absolute frequencies were indicated
by bold characters (Table 2).
Also, we compared the degree of necroinflammatory
activity between chronically infected patients with HCV
genotype 1b versus other genotypes (2, 3a, 4 and mixed). In
this study we found that the patients infected with HCV
genotype 1b had more frequently moderate or severe necro-
inflammatory activity of the disease, a significantly higher
grading score in comparison with other genotypes (χ
2 =
23.67; p < 0.0001) (Figure 1a).
Table 1
Analysis of demographic characteristics of patients with chronic hepatitis C virus infection in
relation to virus genotyp
Genotype n (%) Gender (male/female) Mean age (year) Duration of disease
(year)
Genotype 1b 67 (53%) 37/30 (55%/45%) 41.66±1.516 2.33±0.167
Genotype 2 8 (6%) 4/4 (50%/50%) 53.0±3.30 2.13±0.479
Genotype 3a 32 (26%) 19/13 (59%/41%) 32.06±1.467 2.44±0.265
Genotype 4 8 (6%) 4/4 (50%/50%) 28.88±3.492 2.13±0.479
Mixed genotype 11 (9%) 5/6 (45%/55%) 33.27±2.316 2.36±0.411
Total 126 (100%) 69/57 (55%/45%) 37.94±1.108 2.37±0.134
Table 2
Histopathological manifestation of chronic hepatitis C infection in relation to various viral genotypes 
20
HCV genotypes* Statistical analysis (p value, Fisher's exact test)
HAI 1b 2 3a 4 Mixed 1b vs.
2
1b vs.
3a
1b vs.
4
1b vs.
mixed
2 vs.
3a 2 vs. 4 2 vs.
mixed
3a vs.
4
3a vs.
mixed
4 vs.
mixed
Grading
score
† 4±0.08 3.13±0.54 4.03±0.39 2.75±0.41 3.27±0.384 0.027 0.9201 0.0128 0.0014 0.0271 0.4287 0.3457 0.0398 0.0321 0.0419
Staging
score
‡ 3.1±0.24 2.63±0.99 2.56±0.31 2.13±0.85 2.18±0.644 0.0614 0.2639 0.1830 0.3349 0.0351 0.3447 0.1986 0.1129 0.2134 0.3432
Total
score
(HAI)
§
7.1±0.31 5.75±1.54 6.59±0.59 4.88±1.09 5.45±0.846 0.0096 0.0316 0.0255 0.05 0.1455 0.1911 0.0991 0.4461 0.2847 0.3772
*Mean ± SEM; Statistically significant differences (p < 0.05 or p < 0.01, Fisher's exact test) in mean values or ratios,
respectively, are indicated by bold characters.
†Score of HAI grading - Necroinflammatory scores: A. Periportal or periseptal interface hepatitis (piecemeal necrosis - range 0−4); B. Confluent
necrosis (range 0−6); C. Focal (spotty) lytic necrosis, apoptosis and focal inflammation (range 0−4) ; D. Portal inflammation (range 0−4).
‡Staging of fibrosis: Modified staging: architectural changes, fibrosis and cirrhosis (range 0−6).
§ Score of histological activity index (HAI) components: grading plus staging.Strana 822 VOJNOSANITETSKI PREGLED Volumen 63, Broj 9
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Fig. 1a − Comparison of a degree of necroinflammatory
activity between chronically infected patients with HCV
genotype 1b versus other genotypes (2, 3a, 4 and mixed)
A higher degree of fibrosis was, also, more common in
the patients infected with genotype 1b infection in compari-
son with other genotypes (χ
2 = 12.95, p < 0.05) (Figure 1b).
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Fig. 1b − Comparison of a stage of fibrosis between
chronically infected patients with HCV genotype 1b
versus other genotypes (2, 3a, 4 and mixed)
According to the previous results, the patients infected
with genotype 1b had significantly higher total HAI score in
comparison with other genotypes (χ
2  = 21.73, p < 0.001)
(Figure 1c).
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Fig. 1c − Comparison of total HAI score between
chronically infected patients with HCV genotype 1b
versus other genotypes (2, 3a, 4 and mixed)
There were no significant correlations between necroin-
flammatory activity of the disease and the stage of the fibro-
sis in 1b, 4 and mixed genotype (genotype 1b: r = 0.1151, p
= N.S; genotype 4: r = 0.4187, p = N.S; mixed genotype: r =
0.3111, p = N.S.) (Figure 2a, 2d and 2e). Also, these two pa-
rameters of HAI were significantly correlated in genotype 2
and 3a (genotype 2: r = 0.8944, p < 0.01; genotype 3a: r =
0.3852, p < 0.05) (Figure 2a and 2b).
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Fig. 2a − Correlation between necroinflammatory activity of
disease and stage of the fibrosis in patients with genotype 1b
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Fig. 2b − Correlation between necroinflammatory activity of
disease and stage of the fibrosis in patients with genotype 2
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Fig. 2c − Correlation between necroinflammatory activity of
disease and stage of the fibrosis in patients with genotype 3a
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Fig. 2d − Correlation between necroinflammatory activity of
disease and stage of the fibrosis in patients with genotype 4Volumen 63, Broj 9 VOJNOSANITETSKI PREGLED Strana 823
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Fig. 2e − Correlation between necroinflammatory activity of
disease and stage of the fibrosis in patients with mixed
genotype
None of the histopathological parameters analyzed were
found to be related to age, sex, or the history of drug abuse
(p = N.S.) for each combination (data not shown).
Discussion
Progression to cirrhosis will occur in up to 30% of all
cases 
21 and the risk of developing hepatocellular carcinoma
after longstanding infection is clearly increased 
22. Chronic
HCV infection is often an insidious illness with a slow rate
of progression in the majority of patients during the first two
decades after the acute onset of the disease 
23. The reason
why some people, not others, develop a severe disease may
be determined by the effect of a large number of both host
and viral variables that can influence disease progression.
The recent paper by Datz et al. 
24 suggests that rates of pro-
gression are not always linear and accelerated progression
can occur in same cases without clear triggers, which empha-
sizes the necessity for continuing follow up of patients even
when the disease progression appears to be slow. Host fac-
tors that may play a role include the route of infection, pa-
tient sex, age at time of infection, and alcohol consumption.
Viral factors of relevance include viral genotype 
25, viral
load 
26, and genetic heterogenecity [27], together with coin-
fection with hepatitis B virus 
28 or HIV 
29. Several reports
have suggested a difference in pathogenicity according to
HCV genotype. Silva et al. 
6 in their recent published data
did not find an association between the genotypes of HCV
and the evolution of fibrosis. Pozzato et al. 
30 suggested that
patients with genotype 1b had more severe liver disease
compared to those with genotype 1a.
Ichimura et al. 
31 suggested that genotype 1b was found
more often in patients with chronic liver disease than in HCV
carriers who were identified among apparently healthy blood
donors, whereas the opposite relation was seen for genotype
2a. Yamada, Tanaka et al. 
32 analyzed data for 4 176 patients
with type C chronic liver diseases and suggested that the
prevalence of genotype 1 increased and that of genotype 2
decreased in accordance with the progression of the severity
of chronic liver disease. Kobayashi et al. 
33 concluded that
patients infected with genotype 2 HCV show more favorable
histological outcome compared with those with genotype 1b.
Deterioration of the grade of liver histology during the fol-
low-up period was seen in 68% of the patients with genotype
1 as compared with 41.7% of those with genotype 2 (p <
0.01). Similarly, the deterioration of the stage of liver histol-
ogy was more common in the former group than in the later
one (63% and 38.9%, respectively; p < 0.05). The mean se-
rum HCV RNA titer was significantly higher in the patients
with genotype 1 than in those with genotype 2 (p < 0.001),
and multivariate analysis showed the titer was one of the in-
dependent factors of the deterioration of the stage (p =
0.0044). This phenomenon may be related in part to the dif-
ference in pathogenicity between the two HCV genotypes 
33.
In this study, liver histology was analyzed by assessing
the grade of necroinflammatory process and the stage of fi-
brosis according to the Ishak's scoring system. We found that
patients infected with HCV genotype 1b had more frequently
moderate or severe necroinfalammatory activity of the dis-
ease, significantly higher grading score in comparison with
other genotypes (p < 0.0001).
Also, higher degree of the fibrosis was more common
in patients infected with genotype 1b infection in comparison
with other genotypes (p < 0.05). This study confirmed the re-
sults of other authors reporting that genotype 1b is predomi-
nant in Europe, as well as significantly higher incidence of
viremia in patients with genotype 1b infection in relation to
other HCV genotypes (p < 0.05). Over 70% of patients in-
fected by genotype 1b had more than 2 × 10
6 virus copies in
1 ml of blood, while in the event of genotypes 2, 3a and 4,
the percentage was 40%, 38.5% and 30%, respectively 
34.
This phenomenon may relate in part to the difference of
pathogenicity between the genotypes.
The majority of studies have failed to show a relation-
ship between hepatic necroiflammation and the progression
of fibrosis, but there are studies with conflicting results. Us-
ing the Ishak and modified METAVIR scoring system, Ro-
senberg et al 
35 found that moderate/ severe fibrosis was in-
dependently associated with the severity of necroinflamma-
tion in 275 patients with chronic hepatitis C. Their study in-
cluded 221 patients with predominantly mild hepatitis C and
dual biopsies without intervening treatment and it found that
the intensity of necroinflammation was significant univariate
predictor of fibrosis progression. Whereas patients with fi-
brosis progression (> 2 points on the Ishak's scale) had a
mean necfoinflammatory score of 4.35, the mean score in
patients without progression was 2.55 (p = 0.007). Serra et
al. 
36 in his study described that older age at the time of in-
fection, increases the duration of the disease and alcohol
consumption had a strong association with progression of fi-
brosis. On the other hand, HCV genotype did not seem to be
an important determination for progression of liver disease.
In our study there were no significant correlations be-
tween necroinflammatory activity of disease and stage of the
fibrosis in 1b, 4 and mixed genotype. Also, none of the
histopathological parameters analyzed was found to be re-
lated to age, sex or the history of drug abuse for each combi-
nation. In addition, we should not neglect the fact that the
histopathological result which we got through biopsy doesn't
necessarily reflect the complete state of the liver disease andStrana 824 VOJNOSANITETSKI PREGLED Volumen 63, Broj 9
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severity of liver damage. Namely, sampling variability ac-
counts for the high discordance rate (greater than 20%) be-
tween the stages of fibrosis or grades of activity when biopsy
samples are taken from different parts of the liver at the same
time 
37. Sampling variability of liver fibrosis in chronic
hepatitis C has been recently thoroughly described by
Bedossa et al. 
38. The coefficient of variation of staging of 15
mm biopsy sample, the usual mean length of biopsy samples
in routine, is 55%.
Conclusion
In conclusion, our results suggest that distinct geno-
types of HCV appear to be associated with a particular
manifestation of the disease and that HCV genotypes seem
to be an important determination for the progression of
liver disease. An improved understanding of factors which
determine differences in the natural course of HCV infec-
tion is needed.
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